From a genomic perspective, recent studies have provided insights into the genetic factors that may influence the response to SGLT2 inhibitors identifying genetic biomarkers and pharmacogenomic profiles associated with SGLT2 inhibitor efficacy could inform personalized treatment approaches and optimize therapeutic outcomes for patients with heart failure. Here, SLC5A2 is linked to heart failure.